Home » Soricimed’s Ovarian Cancer Therapy Secures Orphan Drug Status
Soricimed’s Ovarian Cancer Therapy Secures Orphan Drug Status
Canadian drugmaker Soricimed Biopharma has secured orphan drug designation for its peptide SOR-C13 for treatment of ovarian cancer.
SOR-C13 targets TRPV6, a calcium channel prevalent in prostate, breast, lung and ovarian cancer.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May